# Trybeca-1 (NCT03665441)

> Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03665441
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: ERYtech Pharma
- Conditions: Pancreatic Adenocarcinoma
- Interventions: eryaspase; Gemcitabine plus Abraxane; Irinotecan plus 5-FU plus leucovorin
- Enrollment: 512
- Primary outcome: Overall Survival (OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 8

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=trybeca-1-nct03665441

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03665441", "email": "<work email>"}; the inbox owner confirms by the emailed link.